Lupin (LUPIN.NS) Osake Kurssi
Lupin Kurssi
Viimeisten 19 vuoden aikana Lupinn liikevaihto kasvoi 14,9 % vuodessa ja ylsi 279,58 Mrd. INR:een. Osakekohtainen tulos on kasvanut 16,2 % vuodessa viimeisten 19 vuoden aikana. Lupinn nettomarginaali 19,1 % on noussut verrattuna −9,3 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 0,62 %. Jakosuhde on noin 26 % tuloksesta. Osinko on kasvanut 14,0 % vuodessa viimeisten 19 vuoden aikana. Lupinn 12 kuukauden konsensustavoitehinta on 2 397,00 INR, noin yli kurssia 22,9 %. 43 analyytikosta 29 suosittaa ostoa — kokonaiskonsensus on Osta.
Lupin osakekurssi
Lupin liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Lupin -osakkeesta
The business model of Lupin Ltd revolves around the pharmaceutical industry. As a leading global pharmaceutical company, Lupin focuses on developing, manufacturing, and marketing a diverse range of generic and branded pharmaceutical products. With a strong emphasis on research and development, Lupin strives to bring innovative solutions and affordable medications to patients worldwide. The company's business model includes a global presence, strategic partnerships, and a commitment to quality and compliance. Lupin Ltd's extensive product portfolio covers various therapeutic areas, including cardiovascular, central nervous system, dermatology, and respiratory, among others, catering to the healthcare needs of millions of people.
Lupin Ltd is primarily active in the pharmaceutical industry.
The main competitors of Lupin Ltd in the market include companies like Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Cipla Ltd., and Torrent Pharmaceuticals Ltd.
Lupin Ltd. is a renowned pharmaceutical company with a rich history and background. Established in 1968, Lupin has emerged as a global leader in the pharmaceutical industry. The company's relentless focus on innovation and research has paved the way for groundbreaking drug discoveries and cutting-edge formulations. Lupin operates through various business segments, catering to a wide range of therapeutic areas including cardiovascular, respiratory, central nervous system, and anti-infective. With a strong global presence across multiple countries, Lupin has earned a stellar reputation for delivering affordable and high-quality healthcare solutions. Over the years, Lupin Ltd. has consistently showcased its commitment to improving global health outcomes with its diverse portfolio of pharmaceutical products.
Lupin Ltd has accomplished several significant milestones throughout its history. One of the major achievements was the company's successful listing on the Bombay Stock Exchange and the National Stock Exchange of India. Lupin also made notable achievements in the global pharmaceutical industry by receiving various regulatory approvals for its high-quality and affordable generic medications. Furthermore, Lupin has expanded its operations globally by establishing a strong presence in key markets like the United States, Europe, Japan, and other emerging markets. These achievements have reinforced Lupin's position as a leading global pharmaceutical company, delivering innovative healthcare solutions to patients worldwide.
Lupin Ltd, a renowned pharmaceutical company, has a significant global presence. The company primarily operates in various countries and regions, including but not limited to India, United States, Europe, Japan, and South Africa. With its strong foothold in these markets, Lupin Ltd has established itself as a leading player in the pharmaceutical industry.
Lupin Ltd is known for upholding strong values and a robust corporate philosophy. Guided by their core principles, Lupin strives for excellence, integrity, and transparency in all their operations. The company firmly believes in providing high-quality pharmaceutical products that improve the lives of patients globally. With a focus on innovation, Lupin continually invests in research and development to bring cutting-edge healthcare solutions to the market. Dedicated to social responsibility, Lupin actively engages in initiatives for the betterment of society, promoting sustainable development and fostering inclusive growth. Through their unwavering commitment to quality, ethics, and social welfare, Lupin Ltd emerges as an industry leader, delivering value to various stakeholders and ensuring a positive impact on the healthcare sector.
Analyytikot asettavat tällä hetkellä Lupin-osakkeelle keskimääräisen tavoitehinnan 2 338,63 INR (mediaani: 2 397,00 INR), mikä merkitsee +19,9 % viimeisimpään hintaan verrattuna. Konsensus perustuu 43 analyytikkoarvioon.
43 analyytikkoa arvioi tällä hetkellä Lupin-osaketta: 29 suosittaa ostoa, 11 pitoa ja 3 myyntiä.
Nykyisellä valuuttakurssilla Lupin-osake noteerataan hintaan 18,00 EUR (1 950,70 INR).
Lupin-osake (LUPIN.NS) on listattuna 2 pörssissä, muun muassa: NSE (Indien) (LUPIN.NS).
Lupin Ltd is a leading pharmaceutical company based in India. The company's business model is based on the production and distribution of pharmaceutical products and generic medications worldwide. Lupin operates in three business segments: generics, branded products, and carbamazepine. The generics segment is the core of Lupin's business model, offering a wide range of cost-effective alternatives to expensive brand-name medications. Lupin also produces branded products, primarily sold in India, including antibiotics, diabetes medications, and hormonal treatments. The carbamazepine segment specializes in the production of antiepileptic drugs and is a significant part of Lupin's business model. The company also emphasizes research and development, investing a significant percentage of its revenue in the development of new drugs. Lupin has established a global distribution network, with subsidiaries in the US, Europe, and Japan, as well as distribution partners in other countries. The company has made strategic acquisitions and mergers to strengthen its presence in different regions, such as the acquisition of Gavis in 2016 to expand its generics business in the US. Overall, Lupin's business model revolves around the production and distribution of pharmaceutical products and generics worldwide, with a strong emphasis on research and development and a global distribution network.
liikevaihto Lupin on 279,58 Mrd. INR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
voitto Lupin on 53,33 Mrd. INR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Lupin:n hinta-voitto-suhde (P/E) on tällä hetkellä 16,76. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Lupin-osakkeen arvostusta.
Lupin:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,20. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Lupin-osakkeen arvostuskennuslukuna.
Lupin:n Eulpool-laatuscore on 5/10.
Lupin:n ISIN on INE326A01037. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Lupin:n ticker on LUPIN.NS. Tämä pörssinoteeraus käytetään Lupin-osakkeiden kauppaan pörssissä.
Lupin osake
Lupin vertaisryhmä
Lupin Ticker
Lupin FIGI
Kaikki tunnusluvut ja syvällinen analyysi Lupin:sta
Meidän osakeanalyysimme Lupin-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Lupin:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: